SYS6010

DRUG8 trials

Conditions

Advanced Solid TumorsColorectal CancerEGFR-mutated Locally Advanced or Metastatic NSCLCGastric Cancer (GC)Gastrointestinal TumorsLocally Advanced/Metastatic/Recurrent ESCCNSCLCNon-Small Cell Lung Cancer

Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

RecruitingNCT07241936

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2025-11-13End: 2028-10-30Target: 444Updated: 2025-11-28

Phase 2

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not yet recruitingNCT07256509

CSPC Megalith Biopharmaceutical Co.,Ltd.Non-Small Cell Lung Cancer

Start: 2025-11-30End: 2032-06-30Target: 120Updated: 2025-12-05

Phase 3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

RecruitingNCT06927986

CSPC Megalith Biopharmaceutical Co.,Ltd.EGFR-mutated Locally Advanced or Metastatic NSCLC

Start: 2025-03-30End: 2026-08-30Target: 380Updated: 2025-11-17

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Not yet recruitingNCT07376382

CSPC Megalith Biopharmaceutical Co.,Ltd.NSCLC

Start: 2026-03-03End: 2029-06-06Target: 450Updated: 2026-02-02

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Not yet recruitingNCT07406542

CSPC Megalith Biopharmaceutical Co.,Ltd.Recurrent or Metastatic Breast Cancer

Start: 2026-04-01End: 2030-04-01Target: 400Updated: 2026-02-12

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Not yet recruitingNCT07417735

CSPC Megalith Biopharmaceutical Co.,Ltd.Locally Advanced/Metastatic/Recurrent ESCC

Start: 2026-03-18End: 2029-12-31Target: 436Updated: 2026-02-18

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Not yet recruitingNCT07442565

CSPC Megalith Biopharmaceutical Co.,Ltd.Non-Small Cell Lung Cancer

Start: 2026-03-10End: 2031-05-30Target: 506Updated: 2026-03-04

Unknown Phase

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

Active, not recruitingNCT07104877

Fujian Cancer HospitalColorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors